Tempest Therapeutics, Inc. (NASDAQ:TPST – Get Free Report)’s share price was up 8.8% during trading on Monday . The stock traded as high as $1.87 and last traded at $1.85. Approximately 817,063 shares changed hands during trading, a decline of 15% from the average daily volume of 958,676 shares. The stock had previously closed at $1.70.
Wall Street Analysts Forecast Growth
Several equities analysts recently commented on TPST shares. Piper Sandler reissued an “overweight” rating and set a $8.00 price target on shares of Tempest Therapeutics in a research report on Friday, June 21st. HC Wainwright reissued a “buy” rating and set a $47.00 price target on shares of Tempest Therapeutics in a research report on Thursday, June 20th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, Tempest Therapeutics has an average rating of “Buy” and an average target price of $20.75.
Get Our Latest Stock Report on Tempest Therapeutics
Tempest Therapeutics Stock Performance
Tempest Therapeutics (NASDAQ:TPST – Get Free Report) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.08. Equities analysts predict that Tempest Therapeutics, Inc. will post -1.57 EPS for the current year.
Insider Transactions at Tempest Therapeutics
In other Tempest Therapeutics news, CEO Stephen R. Brady purchased 35,000 shares of the firm’s stock in a transaction dated Wednesday, July 3rd. The stock was bought at an average price of $2.11 per share, with a total value of $73,850.00. Following the completion of the purchase, the chief executive officer now owns 46,376 shares in the company, valued at approximately $97,853.36. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Over the last quarter, insiders acquired 47,172 shares of company stock valued at $100,001. 3.27% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On Tempest Therapeutics
An institutional investor recently raised its position in Tempest Therapeutics stock. Virtu Financial LLC boosted its holdings in shares of Tempest Therapeutics, Inc. (NASDAQ:TPST – Free Report) by 69.2% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 28,574 shares of the company’s stock after buying an additional 11,689 shares during the period. Virtu Financial LLC owned approximately 0.13% of Tempest Therapeutics worth $112,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 22.52% of the company’s stock.
Tempest Therapeutics Company Profile
Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.
See Also
- Five stocks we like better than Tempest Therapeutics
- What is the Shanghai Stock Exchange Composite Index?
- Survey: Top 175 Fittest Retirement Locations in America
- Are Penny Stocks a Good Fit for Your Portfolio?
- Kimberly-Clark Stock Dips and a Buying Opportunity Emerges
- How to Use Stock Screeners to Find Stocks
- Leading Gold Stock Shines With Q2 2024 Earnings Release
Receive News & Ratings for Tempest Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempest Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.